Form 4: New Enterprise Associates 17, L.P. Acquires Warrants in NeueHealth, Inc.
SEC Form 4
New Enterprise Associates 17, L.P. reports acquisition of warrants in NeueHealth, Inc. pursuant to a warrantholders agreement and credit agreement.
Summary
- New Enterprise Associates 17, L.P. filed a Form 4 disclosing changes in beneficial ownership of NeueHealth, Inc. securities.
- The report indicates the acquisition of 61,865 warrants with an exercise price of $0.01 on October 1, 2024.
- These warrants are exercisable from October 2, 2024, and expire on April 30, 2029.
- The warrants were issued under a Warrantholders Agreement dated April 8, 2024, and a Credit Agreement dated August 4, 2023, as amended.
- Following the transaction, New Enterprise Associates 17, L.P. directly holds 185,594 warrants.
- The filing also includes information about indirect beneficial ownership by NEA Partners 17, L.P., NEA 17 GP, LLC, and individual managers of NEA 17 GP, who disclaim beneficial ownership except to the extent of their pecuniary interest.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The acquisition of warrants by a major investor is generally a positive sign, but the filing itself is a routine disclosure.
Positives
- The acquisition of warrants by a significant investor like New Enterprise Associates 17, L.P. could be seen as a positive signal for NeueHealth, Inc.
Risks
- The filing itself doesn't inherently indicate risks, but the warrants' value is contingent on NeueHealth, Inc.'s future performance.
- The indirect beneficial owners disclaiming ownership could indicate a complex ownership structure.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders and major shareholders. This filing indicates investment activity by a significant venture capital firm in the healthcare sector.
Comparison to Industry Standards
- Venture capital firms like New Enterprise Associates frequently invest in healthcare companies, often through instruments like warrants.
- The terms of the warrants, such as the exercise price and expiration date, are typical for venture capital investments in growth-stage companies.
- Similar investments can be seen by firms such as Kleiner Perkins, Sequoia Capital, and Andreessen Horowitz in comparable healthcare technology and service companies.
Stakeholder Impact
- Shareholders may view the warrant acquisition as a positive signal, potentially increasing confidence in the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| 2023-08-04 | Date of the Credit Agreement between the Issuer and the lenders thereto. |
| 2023-10-02 | Date of Incremental Amendment No. 1 to the Credit Agreement. |
| 2024-04-08 | Date of the Warrantholders Agreement between the Issuer and the holders listed on Schedule 1 thereto, and Incremental Amendment No. 2 to the Credit Agreement. |
| 2024-10-01 | Transaction date for the acquisition of warrants. |
| 2024-10-02 | Date the warrants become exercisable. |
| 2029-04-30 | Expiration date of the warrants. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.